New combo pill aims to shrink spleens and ease symptoms in bone marrow cancer
NCT ID NCT07357727
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding pelabresib to the standard drug ruxolitinib works better than ruxolitinib alone for people with myelofibrosis, a type of bone marrow cancer. About 460 adults who have not taken JAK inhibitors before will receive either the combination or a placebo plus ruxolitinib. The main goals are to see if the combination shrinks the spleen and reduces symptoms like pain and fatigue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pelabresib (a drug) combined with ruxolitinib (a drug)
What this could lead to
If it works, this combination could offer better control of myelofibrosis by shrinking the spleen and easing symptoms more than the current standard treatment.
What could go wrong
This is a large phase 3 trial, but the added benefit of pelabresib is unproven. Side effects from the combination could be worse than ruxolitinib alone, and the results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MYELOFIBROSIS (PMF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Novartis Investigative Site
RECRUITINGCapital Federal, C1114AAN, Argentina
-
Novartis Investigative Site
RECRUITINGClayton, Victoria, 3168, Australia
-
Novartis Investigative Site
RECRUITINGNantong, Jiangsu, 226000, China
-
Novartis Investigative Site
RECRUITINGWenzhou, Zhejiang, 325000, China
-
Novartis Investigative Site
RECRUITINGBeijing, 100730, China
-
Novartis Investigative Site
RECRUITINGFuzhou, 350001, China
-
Novartis Investigative Site
RECRUITINGTianjin, 300020, China
-
Novartis Investigative Site
RECRUITINGPune, Maharashtra, 411006, India
-
Novartis Investigative Site
RECRUITINGSuwon, Gyeonggi-do, 442-723, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, Yangcheon Gu, 07985, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 03080, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 05505, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 06351, South Korea
-
Novartis Investigative Site
RECRUITINGSeoul, 06591, South Korea
-
Novartis Investigative Site
RECRUITINGBasel, 4058, Switzerland
-
Novartis Investigative Site
RECRUITINGGenolier, 1272, Switzerland
-
Summit Medical Group Oncology
RECRUITINGBerkeley Heights, New Jersey, 07922, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43221, United States
Contact
Contact Email: •••••@•••••